---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-027072"
form_type: "8-K"
ticker: null
cik: "0001460602"
company_name: "Orgenesis Inc."
filed_at: "2024-07-12T23:59:59+00:00"
generated_at: "2026-05-31T21:04:18.800941+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Orgenesis acquires CAR-T IP from Broaden for up to $11M, net of $10.8M debt

## Summary
- Orgenesis buys Broaden's CAR-T, RACE CAR-T process and algorithms, including patents and know-how.
- Consideration capped at $11M, reduced by $10.767M debt Broaden owes Orgenesis for prior work.
- Net consideration (if any) payable in Orgenesis stock at $3/share or 10% above market, or a 24-month note.
- Broaden contracts with Orgenesis Maryland for exclusive perpetual cell therapy processing services.
- All rights under the Dec 2022 JVA, including JV entity shares, transferred to Orgenesis free of charge.

## SEC filing metadata
- accession: 0001493152-24-027072
- form_type: 8-K
- cik: 0001460602
- company_name: Orgenesis Inc.
- filed_at: 2024-07-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1460602/000149315224027072/0001493152-24-027072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1460602/000149315224027072/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-027072
- JSON: https://secwatch.observer/filing/0001493152-24-027072.json
- Plain text: https://secwatch.observer/filing/0001493152-24-027072.txt

## Key facts
- M&A Transactions
  Orgenesis Inc. completed an acquisition involving Broaden Bioscience and Technology Corp. for not to exceed $11,000,000 (closed 2024-07-10).
  - Action: acquisition
  - Counterparty: Broaden Bioscience and Technology Corp.
  - Consideration: not to exceed $11,000,000
  - Closing: 2024-07-10
  source text: the Company will pay Broaden an amount equal to the value of the Assets established by a third party valuation firm selected by the Company (the “Valuation”), not to exceed $11,000,000 (the “Consideration”), less a debt adjustment relating to the $10,767,298 owed to the Company by Broaden for work performed and invoiced between August 2022 and May 2023 (the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1460602/000149315224027072/0001493152-24-027072-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.